Pharmaceutical Polymorphs

Pharmaceutical Polymorphs - Image

Polymorphism is a major concern for the pharmaceutical industry. Everything from efficacy to regulatory applications and intellectual property can be affected by a lack of polymorphic control over an API.

A recent paper by the Hall Group at the University of Bristol has highlighted a new technique for producing ‘disfavoured’ polymorphs (e.g. elusive paracetamol Form II), using “self-destructing” deep eutectic solvents. Mixing the crystallisation target with certain volatile solids produces a lower-boiling mixture which encourages metastable polymorphs to crystallise when the second component evaporates. A very interesting article, with implications throughout the pharmaceutical industry. The Chemistry World summary is here.

To learn more about how Crystec’s mSAS® (modified Supercritical Anti-Solvent) technology platform can be applied to control solid-state form to generate known and new (high pressure) polymorphs, check out our case study or get in touch!